Subgroup analysis suggests survival benefit in patients with advanced liver cancer treated with resminostat
by eazee-designstudio
iOmx Therapeutics raises EUR 40 million in Series A round led by MPM Capital, Sofinnova Partners, Wellington Partners and Merck Ventures
Leading European research groups pool their expertise for the fast development of an effective and affordable vaccine against the Zika virus.
Austrian biotech company Themis Bioscience said it had started a clinical trial of an experimental Zika vaccine in healthy volunteers.
Themis Bioscience: Zika Vaccine Development Receives Big Boost by Innovate UK
To advance novel RIG-I targeted immuno-oncology therapeutics. The company also announced opening of Cambridge, MA office.
Promising scientific data open up new therapeutic combination options for the epigenetic anti-cancer compound resminostat.
NEUWAY Receives €2.95 Million BMBF Grant for Advancing CNS Drug Delivery Platform. CLICK FOR MORE.
New worldwide, exclusive license agreement provides broad access to Institut Pasteur's virus vector technology – Zika vaccine development progressing with high priority
Symetis has announced the acquisition of Middle Peak Medical. Wellington Partners led the Series A investment into Middle Peak in 2013.
